TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7867553

Group type: EXPERIMENTAL
Intervention: SIDS siblings
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 50
Study: 1441705

Group type: EXPERIMENTAL
Intervention: Percutaneously applied collagen (group A; n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional pressure dressing (group B; n = 50)
Number of subjects: 100
Study: 3936086

Group type: EXPERIMENTAL
Intervention: Alcohol (whisky) consumed by experimental subjects, producing approximately 0.08% blood alcohol concentration.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no alcohol consumption).
Number of subjects: 60
Study: 29854372

Group type: EXPERIMENTAL
Intervention: Sulforaphane (derived from broccoli sprouts and seeds), 12-week open-label study
Number of subjects: 15
Study: 29045941

Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 38133

Group type: COMPARATOR
Intervention: Other antihypertensives
Number of subjects: 38133

Group type: EXPERIMENTAL
Intervention: Lower baseline eGFR
Number of subjects: 38133

Group type: EXPERIMENTAL
Intervention: High SBP, age, male gender, smoking
Number of subjects: 38133
Study: 23721750

Group type: EXPERIMENTAL
Intervention: 40 g/l carbohydrate, 20 g/l milk protein solution (CP20)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 g/l carbohydrate, 40 g/l milk protein solution (CP40)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 60 g/l carbohydrate solution (C)
Number of subjects: 8
Study: 20640974

Group type: EXPERIMENTAL
Intervention: African-American women
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Hispanic women
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Caucasian women
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Overall pregnant women
Number of subjects: 494
Study: 19082847

Group type: EXPERIMENTAL
Intervention: Ultraporous beta‐tricalcium phosphate (beta‐TCP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Autogenous iliac crest bone graft (ICBG)
Number of subjects: 40
Study: 17926619

Group type: EXPERIMENTAL
Intervention: Acupuncture between 7:00-11:00 a.m.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture at any time (control group)
Number of subjects: 120
Study: 15569122

Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU b.d.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (alpha-interferon/ribavirin therapy)
Number of subjects: 51
Study: 11512648

Group type: EXPERIMENTAL
Intervention: Sitting Group (intrathecal anaesthesia in sitting position)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lateral Group (intrathecal anaesthesia in lateral position)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 9283675

Group type: EXPERIMENTAL
Intervention: Transparent polyurethane dressings
Number of subjects: 229

Group type: COMPARATOR
Intervention: Gauze dressings
Number of subjects: 229
Study: 8396086

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg od for 3 days)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg tid for 10 days)
Number of subjects: 99
Study: 3094657

Group type: EXPERIMENTAL
Intervention: 30 units of anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (no APSAC)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study: 30558680

Group type: EXPERIMENTAL
Intervention: Short-term cefazolin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term cefazolin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term cefazolin + vancomycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term cefazolin + vancomycin
Number of subjects: 0
Study: 26436865

Group type: EXPERIMENTAL
Intervention: Subcutaneous Immunotherapy (SCIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study: 23184062

Group type: EXPERIMENTAL
Intervention: Interactive videogame distraction with VR helmet
Number of subjects: 62

Group type: COMPARATOR
Intervention: Interactive videogame distraction without VR helmet
Number of subjects: 62
Study: 21852334

Group type: EXPERIMENTAL
Intervention: Home monitoring (HM) with daily spirometry and medical feedback
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Home monitoring (HM)
Number of subjects: 50
Study: 20544649

Group type: EXPERIMENTAL
Intervention: OGU model (acute orthogeriatric unit)
Number of subjects: 224

Group type: COMPARATOR
Intervention: CG model (usual model of care)
Number of subjects: 224
Study: 18689560

Group type: EXPERIMENTAL
Intervention: DietMatePro
Number of subjects: 174

Group type: COMPARATOR
Intervention: Paper food diary
Number of subjects: 174
Study: 15975098

Group type: EXPERIMENTAL
Intervention: IDetmorn+din
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: IDetmorn+bed
Number of subjects: 400

Group type: COMPARATOR
Intervention: NPHmorn+bed
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: IDetmorn+din and IDetmorn+bed
Number of subjects: 400
Study: 12916149

Group type: EXPERIMENTAL
Intervention: Precolposcopy educational sessions
Number of subjects: 47
Study: 10480523

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with CHD
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nondiabetic control subjects
Number of subjects: 70
Study: 9196992

Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (0.1 U/kg of crystalline insulin)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravenous glucose tolerance test (0.3 g glucose/kg followed by 0.02 U/kg of crystalline insulin)
Number of subjects: 11
Study: 1933160

Group type: EXPERIMENTAL
Intervention: Bard Biocath catheter (16 F 10‐ml balloon)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Silastic catheter (16 F 10‐ml balloon)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Bard Biocath catheter (non-encrusted)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Silastic catheter (non-encrusted)
Number of subjects: 69
Study: 7017490

Group type: EXPERIMENTAL
Intervention: guacetisal
Number of subjects: 28

Group type: COMPARATOR
Intervention: dimethylaminophenazone guaiacolglycolate and calcium ethylcamphorate
Number of subjects: 28
Study: 30741854

Group type: EXPERIMENTAL
Intervention: Crowdsourced video intervention
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Social marketing video intervention
Number of subjects: 1173
Study: 27933401

Group type: EXPERIMENTAL
Intervention: Vaginal rifaximin (RFX) for 6 days
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Dequalinium chloride (DQC) for 6 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 24934738

Group type: EXPERIMENTAL
Intervention: Eight-session self-hypnosis training intervention without audio recordings for home practice
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Eight-session self-hypnosis training intervention with recordings
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Two-session self-hypnosis training intervention with recordings and brief weekly reminder telephone calls
Number of subjects: 100

Group type: COMPARATOR
Intervention: Active (biofeedback) control intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hypnosis (combined groups)
Number of subjects: 100
Study: 23900128

Group type: EXPERIMENTAL
Intervention: 800ml oral carbohydrate fluid 8 h before the operation and 400ml oral carbohydrate fluid 2 h before the operation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stopped oral implementation 8 h before the operation
Number of subjects: 40
Study: 21062637

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 600 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketamine (0.26 mg/kg bolus followed by 0.25 mg/kg IV infusion)
Number of subjects: 10
Study: 20027430

Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Panavia F resin-based cement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Post cementation periods (immediate, 72 h, 4 months)
Number of subjects: 60
Study: 17267590

Group type: EXPERIMENTAL
Intervention: Bolus injection of Escherichia coli endotoxin (0.3 ng/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of Escherichia coli endotoxin (0.3 ng/kg over 4 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline administration
Number of subjects: 10
Study: 15598992

Group type: EXPERIMENTAL
Intervention: Body tilt (pitch axis) with varying amplitudes
Number of subjects: 14
Study: 12528557

Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza and shengmai (SS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Obstructive jaundice (OJ) group (no SS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-OJ group
Number of subjects: 15
Study: 9694306

Group type: EXPERIMENTAL
Intervention: 15 min nap
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 45 min nap
Number of subjects: 30

Group type: COMPARATOR
Intervention: No nap
Number of subjects: 30
Study: 8128083

Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 33
Study: 2622724

Group type: EXPERIMENTAL
Intervention: Eyerobics visual skills training for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 769550

Group type: EXPERIMENTAL
Intervention: Tobramycin at a daily dose of 1.2 mg/kg body weight, administered by intramuscular injection at 8 or 12 hour intervals
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 32
Study: 31605377

Group type: COMPARATOR
Intervention: Hand file
Number of subjects: 120

Group type: COMPARATOR
Intervention: ProTaper Universal retreatment file
Number of subjects: 120

Group type: COMPARATOR
Intervention: D‐RaCe retreatment file
Number of subjects: 120

Group type: COMPARATOR
Intervention: Reciproc file
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Reciproc system
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ProTaper Universal retreatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D‐RaCe retreatment
Number of subjects: 120
Study: 31493177

Group type: EXPERIMENTAL
Intervention: Erlotinib induction at 150 mg/day for 3 months followed by cytotoxic chemotherapy (platinum plus pemetrexed, with or without bevacizumab)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Erlotinib induction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chemotherapy after erlotinib induction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 20
Study: 28928574

Group type: EXPERIMENTAL
Intervention: Midline approach LESI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transforaminal approach LESI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paramedian approach LESI
Number of subjects: 60
Study: 25946126

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and PTA 5289 lozenges (108 CFU of each strain/lozenge)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23075031

Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 65% [Vdot]O(2)max
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 75% [Vdot]O(2)max
Number of subjects: 12

Group type: COMPARATOR
Intervention: No-exercise condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treadmill exercise at varying intensities
Number of subjects: 12
Study: 21240026

Group type: EXPERIMENTAL
Intervention: Outpatient treatment program of obesity
Number of subjects: 91

Group type: COMPARATOR
Intervention: Inpatient treatment program of obesity
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Total CTT measurement
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Diet evaluation
Number of subjects: 91
Study: 18496340

Group type: EXPERIMENTAL
Intervention: beta‐TCP combined with local bone obtained from decompression (group A, n = 32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: autogenous iliac crest bone graft plus decompression bone (group B, n = 30)
Number of subjects: 62
Study: 17000194

Group type: EXPERIMENTAL
Intervention: Sainte‐Anne's Hospital reshaped minced‐ or pureed‐texture foods with thickened beverages
Number of subjects: 17

Group type: COMPARATOR
Intervention: Traditional nourishment
Number of subjects: 17
Study: 14530859

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 ppm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (0.35 mg/kg over 20 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both groups (iNO and sildenafil)
Number of subjects: 15
Study: 10965414

Group type: EXPERIMENTAL
Intervention: Digoxin (0.5 mg) with DHEC (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Digoxin (0.5 mg) without DHEC
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Digoxin with DHEC
Number of subjects: 12

Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 12
Study: 8774208

Group type: EXPERIMENTAL
Intervention: Isoniazid chemoprophylaxis (10 to 15 mg/kg, twice-weekly)
Number of subjects: 2960
Study: 1615986

Group type: EXPERIMENTAL
Intervention: Cytobrush‐spatula
Number of subjects: 2015

Group type: EXPERIMENTAL
Intervention: Bayne Pap Brush
Number of subjects: 2015

Group type: COMPARATOR
Intervention: cotton swab‐spatula
Number of subjects: 2015
Study: 6746947

Group type: EXPERIMENTAL
Intervention: Contract/recording
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Contract/recording plus instructions for positive reinforcement
Number of subjects: 25

Group type: COMPARATOR
Intervention: No contract/no recording
Number of subjects: 25
Study: 31922462

Group type: COMPARATOR
Intervention: Collagenase clostridium histolyticum
Number of subjects: 280
Study: 31277694

Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention focused on promoting infant sleeping and self-soothing
Number of subjects: 300

Group type: COMPARATOR
Intervention: Child safety control intervention
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 300
Study: 29029210

Group type: EXPERIMENTAL
Intervention: lesinurad 400 mg daily
Number of subjects: 214

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 214
Study: 25683593

Group type: EXPERIMENTAL
Intervention: Outflow tract PVCs
Number of subjects: 146

Group type: COMPARATOR
Intervention: Non-outflow tract PVCs
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Echocardiographic reverse remodeling
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: PVCs originating from RVOT
Number of subjects: 146
Study: 24529550

Group type: EXPERIMENTAL
Intervention: PTA using paclitaxel-coated balloon (PCB) and plain balloon (PB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PTA using plain balloon (PB) alone
Number of subjects: 10
Study: 21983758

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium thiopental
Number of subjects: 60
Study: 19732677

Group type: COMPARATOR
Intervention: Transbond XT (3M Unitek) with 37% phosphoric acid etching (Control)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Transbond Plus and Transbond XT (3M Unitek)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Clearfil Mega Bond FA and Kurasper F (Kuraray Medical)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Primers A and B, and BeautyOrtho Bond (Shofu)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: AdheSE and Heliosit Orthodontic (Ivoclar Vivadent AG)
Number of subjects: 175
Study: 17362568

Group type: EXPERIMENTAL
Intervention: Automation-assisted cytological screening
Number of subjects: 777144

Group type: COMPARATOR
Intervention: Conventional Papanicoalou (Pap) screening
Number of subjects: 777144
Study: 15010181

Group type: EXPERIMENTAL
Intervention: Active coping (AC) stress task (reaction time task)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Passive coping (PC) stress task (cold-pressor test)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Relaxation control condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active coping (AC) stress task
Number of subjects: 40
Study: 11181149

Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-2 immunotherapy (4.5x106 IU twice daily for 5 days every 6 weeks)
Number of subjects: 13
Study: 9754145

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7841259

Group type: EXPERIMENTAL
Intervention: Letters from general practitioners
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Telephone reminders
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Postal reminders
Number of subjects: 1123
Study: 3346069

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 27

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 27
Study: 29202606

Group type: EXPERIMENTAL
Intervention: Culturally tailored narrative educational videos
Number of subjects: 40
Study: 27016659

Group type: EXPERIMENTAL
Intervention: Active sequential bilateral rTMS
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 49
Study: 26308227

Group type: EXPERIMENTAL
Intervention: Cohort 3: Baseline intervention plus a pharmacist call to members' providers
Number of subjects: 6591

Group type: EXPERIMENTAL
Intervention: Cohort 2: Baseline intervention plus a live outbound intervention call to members by a pharmacist
Number of subjects: 6591

Group type: EXPERIMENTAL
Intervention: Cohort 1: Baseline intervention consisting of member educational mailing and provider educational mail or fax notification
Number of subjects: 6591
Study: 23613825

Group type: EXPERIMENTAL
Intervention: Panax ginseng 1 g day(-1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Panax ginseng 2 g day(-1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Panax ginseng
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Panax ginseng 1 g
Number of subjects: 90
Study: 20945821

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo (saline infusions)
Number of subjects: 156
Study: 17426347

Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS)
Number of subjects: 78

Group type: COMPARATOR
Intervention: NDT/Bobath training
Number of subjects: 78
Study: 15195497

Group type: EXPERIMENTAL
Intervention: Subcutaneous tryptorelin depot (Decapeptyl 3.75)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Subcutaneous tryptorelin acetate daily (Decapeptyl 0.1 mg)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 0.05 mg tryptorelin acetate daily from day 21 of the cycle
Number of subjects: 132
Study: 11468228

Group type: EXPERIMENTAL
Intervention: Vitamin B12 treatment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 9881806

Group type: EXPERIMENTAL
Intervention: Conductive Education (CE)‐based programmes
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional neurodevelopmental programmes
Number of subjects: 34
Study: 8297196

Group type: EXPERIMENTAL
Intervention: Single-dose treatment with 1200 mg of norfloxacin
Number of subjects: 113

Group type: COMPARATOR
Intervention: Multiple-day treatment with 400 mg of norfloxacin twice daily for 7 days
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Spontaneous cure in women with high initial colony count
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Spontaneous cure in women with low initial colony count
Number of subjects: 113
Study: 3177373

Group type: EXPERIMENTAL
Intervention: Continuous vancomycin therapy (1-g loading dose followed by 30 mg/L dialysate effluent)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intermittent vancomycin therapy (2 doses of 30 mg vancomycin/kg body weight, initial dose at diagnosis and second dose 1 week later)
Number of subjects: 90
Study: 4392503

Group type: EXPERIMENTAL
Intervention: Alpha-receptor blocking drugs (phentolamine and phenoxybenzamine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Histamine dihydrochloride (intravenous infusion)
Number of subjects: 20
Study: 29802530

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 831
Study: 27770799

Group type: EXPERIMENTAL
Intervention: Oral bicarbonate to achieve serum bicarbonate levels of 24-28 mmol/L
Number of subjects: 145

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 145
Study: 25773554

Group type: EXPERIMENTAL
Intervention: Maintenance rituximab (MR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (RIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 23020102

Group type: EXPERIMENTAL
Intervention: Educational intervention on caregivers' feeding practices, including enhanced home-prepared recipes and food preparation and hygiene through group training, counselling, and home visits.
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Educational intervention on caregivers' feeding practices.
Number of subjects: 599
Study: 20077145

Group type: EXPERIMENTAL
Intervention: Tobacco Tactics intervention
Number of subjects: 294
Study: 18166490

Group type: EXPERIMENTAL
Intervention: Percutaneous arterial closure device (Prostar(R)) used in group A (19 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional open surgery in control group B (21 patients)
Number of subjects: 40
Study: 16724579

Group type: EXPERIMENTAL
Intervention: Generic formulation of zidovudine (AVIRO-Z 300 mg tablet)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Innovator product (Retrovir tablet)
Number of subjects: 68
Study: 15491235

Group type: COMPARATOR
Intervention: risperidone
Number of subjects: 1150
Study: 11238508

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: 2 mg estradiol plus 10 mg dydrogesterone daily
Number of subjects: 26